On Oct 31, major Wall Street analysts update their ratings for $AbbVie (ABBV.US)$, with price targets ranging from $205 to $240.
Morgan Stanley analyst Terence Flynn maintains with a buy rating, and adjusts the target price from $218 to $231.
J.P. Morgan analyst Chris Schott maintains with a buy rating, and maintains the target price at $210.
BofA Securities analyst Charlie CY Yang maintains with a hold rating, and sets the target price at $210.
Citi analyst Geoff Meacham upgrades to a buy rating, and adjusts the target price from $172 to $226.
Barclays analyst Carter Gould maintains with a buy rating, and maintains the target price at $212.
Furthermore, according to the comprehensive report, the opinions of $AbbVie (ABBV.US)$'s main analysts recently are as follows:
After AbbVie reported strong Q3 results and enhanced its revenue guidance for 2024, there's a positive sentiment regarding the company's prospects towards the year-end. This sentiment is supported by a favorable EPS outlook for 2025. However, the assessment of the company's long-term growth potential is tempered by considerations of its present market valuation.
The increase in growth outlook confidence continues, according to an analyst, following AbbVie's strong Q3 performance. The raised estimates are primarily driven by the anticipation for higher Rinvoq/Skyrizi sales, though this is slightly balanced by the reduced forecasts for aesthetics and Humira.
The company reported another robust quarter, which supports a positive outlook on its shares, bolstered by numerous pipeline events and strong commercial momentum looking towards 2025.
Here are the latest investment ratings and price targets for $AbbVie (ABBV.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月31日，多家華爾街大行更新了$艾伯維公司 (ABBV.US)$的評級，目標價介於205美元至240美元。
摩根士丹利分析師Terence Flynn維持買入評級，並將目標價從218美元上調至231美元。
摩根大通分析師Chris Schott維持買入評級，維持目標價210美元。
美銀證券分析師Charlie CY Yang維持持有評級，目標價210美元。
花旗分析師Geoff Meacham上調至買入評級，並將目標價從172美元上調至226美元。
巴克萊銀行分析師Carter Gould維持買入評級，維持目標價212美元。
此外，綜合報道，$艾伯維公司 (ABBV.US)$近期主要分析師觀點如下：
在艾伯維公司報告強勁的第三季度業績並提高了2024年的營業收入指引後，人們對公司的前景對年底持樂觀態度。這種情緒得到了2025年積極的每股收益展望的支持。然而，對公司長期增長潛力的評估受到了當前市值考慮的限制。
根據分析師的說法，隨着艾伯維公司強勁的第三季度業績，增長前景的信心繼續提升。提高的預期主要是由對Rinvoq/Skyrizi銷售的期待推動的，儘管這在一定程度上被對美學和Humira減少的預測所平衡。
公司再次報告了強勁的一個季度，這支持了對其股票的積極展望，受到衆多管道活動和朝2025年積極商業勢頭的支持。
以下爲今日7位分析師對$艾伯維公司 (ABBV.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
